AQST

Aquestive Therapeutics Inc

Add to Watchlist

Advanced Chart

3.895

-0.005(-0.128%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.970

Open

3.9188

VWAP

3.93

Vol

289.87K

Mkt Cap

387.38M

Low

3.885

Amount

1.14M

EV/EBITDA(TTM)

Total Shares

91.04M

352.49M

EV/OCF(TTM)

P/S(TTM)

6.63

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

11.32M

-43.68%

-0.173

+1203.23%

12.20M

-9.95%

-0.157

+43.73%

12.81M

+7.92%

-0.140

-12.88%

Estimates Revision

The market is revising Downward the revenue expectations for Aquestive Therapeutics, Inc. (AQST) for FY2025, with the revenue forecasts being adjusted by -9.11% over the past three months. During the same period, the stock price has changed by 36.67%.

Revenue Estimates for FY2025

Revise Downward

-9.11%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+7.29%

In Past 3 Month

Stock Price

Go Up

+36.67%

In Past 3 Month

8 Analyst Rating

69.70% Upside

Wall Street analysts forecast AQST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AQST is 6.61 USD with a low forecast of 4.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

1 Hold

0 Sell

Strong Buy

69.70% Upside

Current: 3.895

Low

4.50

Averages

6.61

High

10.00

69.70% Upside

Current: 3.895

Low

4.50

Averages

6.61

High

10.00

Oppenheimer

Outperform

Hold

downgrade

$15 -> $7

2025-06-02

Reason

Oppenheimer

Price Target

$15 -> $7

2025-06-02

downgrade

Outperform

Hold

Reason

Oppenheimer lowered the firm's price target on Aquestive Therapeutics to $7 from $15 and keeps an Outperform rating on the shares following quarterly results. With the Anaphylm NDA submitted on April 1, management expects an FDA response next month and a potential action date in late January/early February 2026. Preparations for a potential AdCom are ongoing. The firm is encouraged by ongoing commercialization efforts, including commercial team build-out, growing anaphylaxis awareness, and continuing payer engagements. Aquestive also plans to engage ex-U.S. regulators and pursue partnerships to strengthen its balance sheet, adds Oppenheimer.

Oppenheimer

Outperform

Underperform

downgrade

$15 -> $7

2025-06-02

Reason

Oppenheimer

Price Target

$15 -> $7

2025-06-02

downgrade

Outperform

Underperform

Reason

Oppenheimer assumed coverage of Aquestive Therapeutics with an Outperform rating with a price target of $7, down from $15, following quarterly results. With the Anaphylm NDA submitted on April 1, management expects an FDA response next month and a potential action date in late January/early February 2026. Preparations for a potential AdCom are ongoing. The firm is encouraged by ongoing commercialization efforts, including commercial team build-out, growing anaphylaxis awareness, and continuing payer engagements. Aquestive also plans to engage ex-U.S. regulators and pursue partnerships to strengthen its balance sheet, adds Oppenheimer.

Piper Sandler

Overweight

downgrade

$8 -> $5

2025-05-13

Reason

Piper Sandler

Price Target

$8 -> $5

2025-05-13

downgrade

Overweight

Reason

Piper Sandler lowered the firm's price target on Aquestive Therapeutics to $5 from $8 and keeps an Overweight rating on the shares.

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$10

2025-04-02

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$10

2025-04-02

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$10

2025-03-10

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$10

2025-03-10

Reiterates

Strong Buy

Reason

Lake Street

Thomas Flaten

Strong Buy

Maintains

$10 → $8

2025-03-07

Reason

Lake Street

Thomas Flaten

Price Target

$10 → $8

2025-03-07

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Aquestive Therapeutics Inc (AQST.O) is -6.39, compared to its 5-year average forward P/E of -4.22. For a more detailed relative valuation and DCF analysis to assess Aquestive Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.22

Current PE

-6.39

Overvalued PE

-1.62

Undervalued PE

-6.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.22

Current EV/EBITDA

-7.20

Overvalued EV/EBITDA

-2.72

Undervalued EV/EBITDA

-9.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

3.86

Current PS

8.08

Overvalued PS

6.12

Undervalued PS

1.60

Financials

Annual

Quarterly

FY2025Q1

YoY :

-27.65%

8.72M

Total Revenue

FY2025Q1

YoY :

+116.20%

-19.37M

Operating Profit

FY2025Q1

YoY :

+78.75%

-22.93M

Net Income after Tax

FY2025Q1

YoY :

+41.18%

-0.24

EPS - Diluted

FY2025Q1

YoY :

+126.02%

-23.54M

Free Cash Flow

FY2025Q1

YoY :

-8.60%

58.12

Gross Profit Margin - %

FY2025Q1

YoY :

+75.08%

-90.43

FCF Margin - %

FY2025Q1

YoY :

+147.07%

-262.96

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

214.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

2.9M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

4.5M

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

214.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

AQST News & Events

Events Timeline

2025-07-22 (ET)

2025-07-22

07:03:02

Aquestive Therapeutics promotes Korczynski to Chief Commercial Officer

2025-07-15 (ET)

2025-07-15

07:05:11

Aquestive Therapeutics provides international expansion update for Anaphylm

2025-06-25 (ET)

2025-06-25

07:13:11

Aquestive Therapeutics announces two presentations on Anaphylm

News

9.0

07-15Newsfilter

Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film

9.0

07-15SeekingAlpha

Aquestive's Anaphylm to be reviewed by Health Canada

1.0

07-07Newsfilter

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

People Also Watch

Blue Ridge Bankshares Inc

Primis Financial Corp

Resources Connection Inc

FAQ

What is Aquestive Therapeutics Inc (AQST) stock price today?

The current price of AQST is 3.895 USD — it has decreased -0.13 % in the last trading day.

AQST

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

AQST News & Events

Events Timeline

News

People Also Watch

FAQ

What is Aquestive Therapeutics Inc (AQST) stock price today?

What is Aquestive Therapeutics Inc (AQST)'s business?

What is the price predicton of AQST Stock?

What is Aquestive Therapeutics Inc (AQST)'s revenue for the last quarter?

What is Aquestive Therapeutics Inc (AQST)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Aquestive Therapeutics Inc (AQST)'s fundamentals?

How many employees does Aquestive Therapeutics Inc (AQST). have?

What is Aquestive Therapeutics Inc (AQST) market cap?